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Regulatory T cells (Tregs) are considered key players in the prevention of allograft rejec-
tion in transplanted patients. Belatacept (BLT) is an effective alternative to calcineurin 
inhibitors that appears to preserve graft survival and function; however, the impact of this 
drug in the homeostasis of Tregs in transplanted patients remains controversial. Here, we 
analyzed the phenotype, function, and the epigenetic status of the Treg-specific demeth-
ylated region (TSDR) in FOXP3 of circulating Tregs from long-term kidney transplant 
patients under BLT or Cyclosporine A treatment. We found a significant reduction in the 
proportion of CD4+CD25hiCD127lo/−FOXP3+ T cells in all patients compared to healthy 
individual (controls). Interestingly, only BLT-treated patients displayed an enrichment of 
the CD45RA+ “naïve” Tregs, while the expression of Helios, a marker used to identify 
stable FOXP3+ thymic Tregs remained unaffected. Functional analysis demonstrated that 
Tregs from transplanted patients displayed a significant reduction in their suppressive 
capacity compared to Tregs from controls, which is associated with decreased levels of 
FOXP3 and CD25. Analysis of the methylation status of the FOXP3 gene showed that 
BLT treatment results in methylation of CpG islands within the TSDR, which could be 
associated with the impaired Treg suppression function. Our data indicate that analysis 
of circulating Tregs cannot be used as a marker for assessing tolerance toward the 
allograft in long-term kidney transplant patients. Trial registration number IM103008.
Keywords: transplantation, tolerance, belatacept, cyclosporine a, Treg, suppression
Abbreviations: CNI, calcineurin inhibitors; CsA, Cyclosporine A; BLT, belatacept; Tregs, regulatory T cells; FOXP3, Forkhead 
box P3; IL-2, interleukin 2; APC, antigen-presenting cell; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; PBMCs, 
Peripheral blood mononuclear cells; CFSE, Carboxy fluorescein succinimidyl ester; FBS, fetal bovine serum.
2Alvarez Salazar et al. Altered Tregs in Belatacept-Treated Patients
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 219
inTrODUcTiOn
Kidney transplantation is considered the treatment of choice 
for patients with end-stage renal failure. The use of calcineurin 
inhibitors (CNI) such as Cyclosporine A (CsA) and tacrolimus 
reduce allograft rejection (1); however, the toxic effect produced 
by the prolonged use of these immunosuppressive drugs, has 
aimed researchers to develop new drugs that prevent allograft 
rejection without the side effects of CNI (2). Among them, 
belatacept (BLT), a human fusion protein combining a modi-
fied extracellular portion of cytotoxic T-lymphocyte-associated 
antigen 4 (CTLA-4) with the constant-region fragment (Fc) 
of human IgG1, was approved in 2011 by US Food and Drug 
Administration as therapeutic agent for the prevention of allo-
graft rejection. BLT mediates its function by interacting with 
costimulatory ligands CD80/CD86 on the antigen-presenting cell 
(APC), thereby blocking the costimulatory signal (second signal) 
required for naive T cell activation and resulting in anergy or 
apoptosis (3). A lower incidence of chronic allograft nephropathy, 
favoring BLT compared to patients under CsA treatment was 
documented by 12 months post-transplantation (4, 5). Although, 
it has been reported an increase of acute rejection episodes and 
post-transplant lymphoproliferative disorders in BLT-treated 
patients (4), clinical studies have shown that 7 years after trans-
plantation kidney transplant patients under BLT treatment have 
a significantly better patient and graft survival, as well as mean 
estimated glomerular filtration rate than patients under CsA (6).
Regulatory T cells (Tregs) are cells with immunosuppressive 
capacity that are important in tolerance maintenance after organ 
transplantation (7). These cells are characterized by the expression 
of the transcription factor FOXP3, considered the master regulator 
of their development and function, as well as high levels of surface 
CD25, and low levels of CD127 (CD4+CD25hiCD127lo/−FOXP3+). 
Therefore, several studies have addressed the potential effects of 
immunosuppressive therapy on Tregs from transplanted patients.
Some studies have claimed that BLT, rather than acting as 
immunosuppressor, plays a role as immunomodulator. This 
was supported by studies showing an increase of CD16+IDO+ 
cells and Tregs in peripheral blood and in intragraft FOXP3+ 
cells, proposed to generate a tolerant profile to renal allograft 
in those patients (8, 9). Other studies showed no differences in 
the percentage of CD4+CD25hi and in FOXP3 levels in the CD4+ 
subpopulation between BLT and CsA patients after 6 months of 
treatment (10) or showed no long-term negative impact of BLT 
on circulating Tregs (11). By contrast, other studies reported a 
lower percentage of CD4+CD25hi cells in peripheral blood and a 
reduced intragraft level of FOXP3 mRNA compared to CsA (12). 
However, it was argued that the negative effect of BLT might 
be the result of short-term effect of the basiliximab used in the 
induction therapy. Therefore, the effect of this drug on Tregs 
remains controversial [reviewed in Ref. (13)].
As BLT is a costimulation blocker, it could interfere with 
signaling pathways (CD28 and CTLA-4) important for the devel-
opment, homeostasis, and function of Tregs (14, 15). As these 
cells are important in tolerance maintenance after organ trans-
plantation (7), it is necessary to study not only their frequency but 
also their suppressor function and FOXP3 epigenetic status, in 
transplanted patients under long-term therapy. Thus, the aim of 
the present study was to analyze the impact of long-term therapy 
with BLT or CsA on the phenotype, suppressive function, and 
the epigenetic status of the FOXP3 TSDR from peripheral Tregs 
of kidney transplant patients with stable graft function. Our data 
indicate that analysis of circulating Tregs cannot be used as a 
marker for assessing tolerance toward the allograft in long-term 
kidney transplant patients.
MaTerials anD MeThODs
Kidney Transplant Patients
Thirty-five primary kidney transplant patients included in this 
sub-study participated in the clinical trial BENEFIT (IM103008 
study), which continue on their original study drug arm, BLT 
(n = 24) or CsA (n = 11). All patients received induction therapy 
with basiliximab, and adjunctive maintenance therapy with 
mycophenolate mofetil and prednisone. BLT was administered 
at a dose of 5  mg/kg every 4  weeks and CsA in an adequate 
dosage to maintain a blood level of 100–200  ng/dl (current 
mean blood level of 132.8 ± 40.1, 65.6–189.4). The current daily 
dose for mycophenolate mofetil and prednisone in both groups 
was 1 g/day and 5 mg/day, respectively. The daily exposure to 
mycophenolate mofetil and prednisone was comparable in both 
groups.
This sub-study was conducted with authorization of Bristol-
Myers Squibb (protocol IM103-351) and approval from the 
Committees Medical Ethics at the Instituto de Investigaciones 
Biomédicas (UNAM), the Instituto Nacional de Ciencias 
Médicas y Nutrición Salvador Zubirán (Reference number 1535), 
the Instituto Nacional de Cardiología Ignacio Chávez, and the 
Instituto Mexicano de Trasplantes, and performed in accordance 
with the revised Declaration of Helsinki content, the Declaration 
of Istanbul, and Good Clinical Practice Guidelines. All patients 
provided written informed consent to participate in the study.
The transplanted individuals had stable graft function and 
with no clinical/biochemical evidence of rejection. Transplanted 
individuals in this sub-study had a mean of 7 years post-trans-
plant. Buffy coat preparations of normal blood donors (control 
group) were provided by the Blood Bank, Instituto Nacional de 
Enfermedades Respiratorias, México DF.
reagents
Anti-CD127-PECy7, anti-CD25-PECy5, anti-CD45RA-APCH7, 
anti-CD19-FITC, and anti-CD3-APCCy7 were purchased 
from BD Biosciences (San Jose, CA, USA). Anti-CD4-PE and 
anti-CD8-PECy7 were purchased from Tonbo Biosciences (San 
Diego, CA, USA). Anti-FOXP3-AlexaFluor647 was purchased 
from Beckman Coulter (Brea, CA, USA). Carboxy fluorescein 
succinimidyl ester (CFSE) was purchased from Life Technologies 
(Eugene, OR, USA).
For intracellular staining, FOXP3/Transcription Factor 
Staining Buffer Set (eBiosciences, San Diego, CA, USA) was used. 
All staining were performed in RPMI 1640 (Gibco, Carlsbad, 
CA, USA) with 10% fetal bovine serum (FBS), 2 mM glutamine, 
10 mM HEPES, and 10 mM antibiotic-anti-mycotic (Gibco).
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cell isolation, antibody staining, and cell 
sorting
Peripheral blood mononuclear cells (PBMCs) were isolated 
from blood of patients or from the buffy coat preparations of 
healthy donors by standard Ficoll-Paque™ Plus density-gradient 
centrifugation (GE Healthcare). PBMCs were labeled with anti-
CD4, anti-CD127, anti-CD25, and anti-CD45RA monoclonal 
antibodies, incubated at 4°C in the dark for 20 min. For intracel-
lular staining, cells were permeabilized with 150 μL of fixation/
permeabilization solution at 4°C for 12 h. After two washes with 
permeabilization buffer 1×, PBMCs were incubated with anti-
FOXP3 and anti-Helios for 30 min at 4°C in the dark. Samples 
were acquired with an Attune® Acoustic Focusing Cytometer 
(Life Technologies) and FlowJo 7.6.2 software (Tree Star, Ashland, 
OR, USA) was used for data analysis. A total of 100,000 events 
were acquired for analysis, after gating of lymphocytes based on 
the FSC/SSC dot plot.
For sorting, 50 ×  106 PBMCs were washed once and resus-
pended in media (RPMI/10% FBS) at 100 ×  106 per ml. Cells 
were incubated with anti-CD4 and anti-CD25 at 4°C for 30 min, 
washed twice and resuspended in PBS 1×. Labeled cells were 
sorted using a FACs Aria I sorter (BD Biosciences). For Treg iso-
lation, a CD4+CD25veryhi gate was used and sorted cells were col-
lected in media (RPMI/20% FBS), washed once and resuspended 
in culture media until ready to be plated in the suppression assay.
T cell suppression assays
As a significant percentage of the patient’s Tregs did not express 
low levels of CD127, we were unable to use the conventional 
CD4+CD25hiCD127lo region to purify Tregs, and instead a 
CD4+CD25veryhi gate (containing >85% of Foxp3+ T cells) was 
used to isolate Tregs from both healthy subjects or kidney trans-
plant patients (see Figure S3 in Supplementary Material). Sorted 
Tregs were cocultured with CD3+ cells (Tresp) from the same 
individuals. CD3+ T cells were isolated by negative selection using 
a Pan T cell Isolation Kit (Miltenyi Biotec, San Diego, CA, USA) 
according to the manufacturer’s instructions, then labeled with 
2.5 μM of CFSE at 37°C for 15 min, and finally washed three times 
with RPMI 10% FBS. In all assays, 5 × 104 CFSE-labeled Tresp 
were cocultured with Tregs at ratios Tregs:Tresp (0:1, 1:2, 1:4, 1:8, 
and 1:16) in RPMI media supplemented with 10% human AB 
serum and in the presence of Human Treg Suppression Inspector 
beads (Miltenyi Biotec) at a bead:Tresp ratio of 1:1. After 5 days, 
cells were stained with antibodies to CD4 and CD8, and cells 
were acquired with an Attune® Acoustic Focusing Cytometer and 
FlowJo 7.6.2 software was used for data analysis. The percentage 
of proliferating Tresp cells was determined by CFSE dilution 
and unlabeled CFSE-negative Tregs were excluded. Suppression 
was calculated as relative inhibition using the following for-
mula: [(Tresp proliferation without Tregs − Tresp proliferation 
with Tregs)/Tresp proliferation without Tregs] ×  100, for each 
individual.
cytokine Production assay
The levels of the cytokines IL-2 and IFN-γ in the culture superna-
tants from suppression assay were measured using LEGENDplex 
bead-based immunoassay KIT (Biolegend), according to the 
recommended procedure. Briefly, the samples were incubated 
with a panel of capture beads, then mixed with biotinylated 
detection antibody and subsequently with streptavidin–phy-
coerythrin, providing flourescent signals that were quantified 
on a flow cytometer. The concentrations of the cytokines were 
determined using a standard curve generated in the same assay. 
The experiments were performed in quadruplicate and repeated 
two times.
Dna Methylation analysis of the FOXP3 
TsDr
Methylation of Treg-specific demethylated region (TSDR) 
of FOXP3 gene was evaluated in isolated CD4+CD25hi from 
transplanted patients and controls previously used for sup-
pression assays (CD4+CD25veryhi gate). As negative controls, 
CD4+CD25−CD45RA+ T cells from controls were included. 
Sodium bisulfite modification of genomic DNA was carried 
out using the EZ DNA Methylation direct Kit (Zymo Research 
Corp., USA) according to the manufacturer’s protocol. 
Bisulfite-treated DNA was PCR amplified using the following 
primers: p-5′-TGTTTGGGGGTAGAGGATTT-3′ and o-5′-
TATCACCCCACCTAAACCAA-3′. Amplified DNA product was 
gel purified using QIAEX II gel extraction kit (Qiagen, Germany) 
and cloned into pGEM-T easy vector (Promega). Escherichia coli 
competent cells were transformed with recombinant vector 10 
individual positive bacterial colonies were selected from which 
recombinant plasmid DNA was purified and sequenced with 3500 
Genetic Analyzer (Applied Biosystems, USA). Sequences were 
interpreted using the Bioedit Software 7.2.5 (Ibis Biosciences, 
USA).
statistical analysis
The statistical analysis was performed using Prism 5.0 soft-
ware (GraphPad Software, San Diego, CA, USA). Values were 
expressed as mean ± SEM. The Kolmogorov–Smirnov test was 
used to evaluate the distribution of each parameter. Only the con-
trol group followed a normal distribution. Differences between 
three groups were calculated using the Kruskal–Wallis test and 
comparison between two groups were made using the two tailed, 
Mann–Whitney non-parametric U test. A value of p < 0.05 was 
considered significant.
resUlTs
Kidney Transplant Patients
Twenty-four patients were included in the BLT group and 
11 patients were in the CsA group. Clinic and demographic 
characteristics of the patients included in the study are shown 
in Table 1. As observed in this Table, no differences were found 
in donor and patients characteristics, although patients under 
BLT treatment maintained significantly better and stable graft 
function (both serum creatinine and cGFR) compared to patients 
under CsA. All patients were included at comparable years after 
transplantation. There were no differences in the total number of 
FigUre 1 | increased frequency of naïve cD4+ T cells in BlT-treated patients. (a) Normal percentages of CD3+, CD4+, and CD8+ cells are found in BLT- 
(n = 24) and CsA- (n = 11) treated patients compared to control (n = 9), and a slight reduction of B (CD19+) cells is observed in BLT-treated patients. (B) Analysis of 
naïve T cell populations by the expression of CD45RA marker shows a significant increase in the frequency of CD4+CD45RA+ naïve T cells in BLT compared to 
CsA-treated kidney transplant patients and controls. Statistical analysis was performed using non-parametric Mann–Whitney test, two tailed. BLT, belatacept; CsA, 
Cyclosporine A. Control group was composed by healthy individuals.
TaBle 1 | clinic and demographic characteristics of kidney transplant patients and controls.
Belatacept (n = 24) csa (n = 11) control (n = 9) p value
Age (years) 31.08 ± 10.1 (18–57) 28.9 ± 10.7 (18–50) 35 ± 10.5 (24–54) 0.565
Gender (F/M) 10/14 3/8 1/8 0.478
Donor age (years) 36.12 ± 9.47 (21–54) 37.81 ± 9.34 (23–52) NA 0.625
Donor gender (F/M) 17/7 6/5 NA 0.451
Haplotypes (2-H/1-H/0-H) 2/14/8 2/6/3 NA 0.755
ESRD cause Unk: 18 Unk: 9 NA 0.672
DM: 3 DM: 0
GMN: 3 GMN: 2
1-year SCr post-KT (mg/dl) 1.05 ± 0.19 (0.7–1.4) 1.34 ± 0.27 (0.95–1.83) NA 0.0011
Current SCr (mg/dl) 1.03 ± 0.304 (0.66–2.03) 1.48 ± 0.43 (0.9–2.1) NA 0.0012
1-year post-KT cGFR (ml/min) by MDRD 79.01 ± 15.6 (56.1–126.2) 63.81 ± 9.1 (50.9–78.9) NA 0.0056
Current cGFR (ml/min) by MDRD 79.6 ± 16.5 (40.1–107.7) 56.8 ± 13.6 (38.1–76.1) NA 0.0004
1-year post-KT serum CsA blood level (ng/ml) NA 155.9 ± 36.2 (112–228.7) NA
Current serum CsA blood level (ng/ml) NA 132.8 ± 40.1 (65.6–189.4) NA
Time since transplantation (years) 7.28 ± 0.91 (5.9–8.67) 7.11 ± 0.83 (5.9–8.22) NA 0.606
Peripheral blood lymphocytes (cells/μl blood) 3.2 ± 1.7 × 103 2.5 ± 1.0 × 103 2.5 ± 0.5 × 103 0.478
ESRD, end-stage renal disease; Unk, unknown; GMN, glomerulonephritis; DM, diabetes mellitus; SCr, serum creatinine; KT, kidney transplant; cGFR, glomerular filtration rate; 
MDRD, modification of diet in renal disease; CsA, cyclosporine A; NA, not available.
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HLA mismatches. The control group consisted of a group of nine 
healthy individuals (eight males and one female) closely matched 
with kidney transplant patients for age, with a mean of 35 years 
(24–54  years). Furthermore, the current number of peripheral 
blood lymphocytes was comparable between both transplant 
groups (3.2  ±  1.7  ×  103 cells/μl blood and 2.5  ±  1.0  ×  103 
cells/μl blood for BLT and CsA, respectively) and to controls 
(2.5 ± 0.5 × 103 cells/μl blood).
Patients under BlT Treatment Present 
high Frequency of circulating 
cD4+cD45ra+ T lymphocytes
No significant differences were found between the frequencies 
of peripheral lymphocytes (CD3+, CD3+CD4+, CD3+CD8+, 
and CD19+ cells) among patients with BLT and CsA compared 
with controls (Figure 1A). Although the frequency of CD4+ T 
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cells was similar between all groups (Figure 1B, left), patients 
on long-term BLT treatment presented significantly higher 
percentages of circulating CD4+CD45RA+ T lymphocytes 
compared with CsA and control groups (BLT = 61.04 ± 3.74; 
CsA  =  48.03  ±  3.97; control  =  40.56  ±  4.92; p  <  0.05) 
(Figure 1B, right).
Decreased Frequency of FOXP3+ and 
reduced expression of FOXP3 and cD25 
inside of Total cD4+ T cells from BlT-
Treated Patients
To examine the effect of BLT versus CsA on the frequency of cir-
culating Tregs in kidney transplant patients, we first analyzed the 
expression of FOXP3 in total CD4+ T cells. Within the CD4+ T cell 
population, the percentage of FOXP3+ cells in both transplanted 
patients was significantly reduced compared with control group 
(BLT = 5.81 ± 0.47; CsA = 4.57 ± 0.32; control = 7.94 ± 0.48; 
p  <  0.01) (Figure  2A). In addition, the expression [mean 
fluorescence intensity (MFI)] of FOXP3 in CD4+FOXP3+ T 
cells from BLT-treated patients was lower than those of CsA and 
controls groups (BLT = 28,731 ± 3,639; CsA = 42,362 ± 6,687; 
control = 49,964 ± 3,108; p < 0.005) (Figure 2B, upper panel). 
As high expression of CD25 characterizes Tregs, we next analyzed 
CD25 within the CD4+ FOXP3+ T cells population and found 
that this marker was significantly reduced in BLT-treated patients 
compared with CsA and control groups. There was no difference 
of CD25 MFI between CsA and controls (BLT = 12,509 ± 839.1; 
CsA =  18,612 ±  2,728; control =  16,111 ±  808.6; p <  0.05) 
(Figure 2B, lower panel).
Frequency of Peripheral 
cD4+cD25hicD127lo/− Tregs from Kidney 
Transplant Patients are reduced  
and express lower levels of FOXP3  
and cD25
Some reports indicate that a CD25hi and CD127lo/− phenotype 
on CD4+ T cells allows more accurately to distinguish Tregs 
from activated CD25+ conventional T cells, particularly in 
human samples (16). As shown in Figure  3A, the propor-
tion of CD25hiCD127lo/− T cells within the CD4+ region was 
significantly reduced in both BLT- and CsA-treated patients 
compared with the control group (BLT  =  3.31  ±  0.25; 
CsA = 3.83 ± 0.51; control = 5.28 ± 0.36; p < 0.05). As a result, 
the frequency of CD25hiCD127lo/−FOXP3+ T cells among CD4+ 
cells was significantly reduced in both treatment groups com-
pared with controls (BLT = 2.81 ± 0.22; CsA = 2.97 ± 0.44; 
control =  4.69 ±  0.36; p <  0.05) (Figure  3B). In addition, 
the expression of FOXP3 in CD4+CD25hiCD127lo/−FOXP3+ 
T cells of transplanted patients was lower than those of 
controls (BLT = 29,099 ± 5,020; CsA = 36,840 ± 9,520; con-
trol =  65,997 ±  5,026; p <  0.05) (Figure  3C, upper panel). 
Expression of CD25 within the CD4+CD25hiCD127lo/−FOXP3+ 
population was significantly reduced in BLT-treated patients 
compared with CsA and control groups (BLT = 20,701 ± 1,363; 
CsA =  28,447 ±  3,859; control =  24,389 ±  1,154; p <  0.05) 
(Figure 3C, lower panel).
Moreover, in order to examine whether the reduced expression 
of FOXP3 and CD25 is the result of changes in the composition 
of the total Treg pool, we determined the frequency of CD45RA+ 
and Helios+ within the CD4+CD25hiCD127lo/−FOXP3+ T cells of 
kidney transplant patients and controls. Similarly to what was 
observed for total CD4+ T cells, BLT-treated patients showed 
a significantly increased frequency of CD4+CD25hiCD127lo/− 
FOXP3+CD45RA+ T cells (“naïve” Tregs) compared with 
control group (BLT =  50.76 ±  3.89; CsA =  43.34 ±  5.19; con-
trol = 30.78 ± 5.41; p = 0.009) (Figure 4A). Interestingly, both 
CD45RA+ and CD45RA− Tregs from BLT-treated patients display 
lower levels of FOXP3 compared to the controls (Figures 4B,C), 
so that our results are not a consequence of the accumulation of 
Tregs with naïve phenotype.
No differences between groups were observed regard-
ing the frequency of Helios+ Tregs (Figure  5A) within the 
CD4+CD25hiCD127lo/−FOXP3+ subpopulation. Furthermore, 
FOXP3 was similarly downregulated in BLT-treated patients 
among Helios+ and Helios− Tregs compared to controls 
(Figures 5B,C). This transcription factor has been recently shown 
to cooperate with FOXP3 to promote Treg suppression function, 
suggesting that it could be a useful marker for the identification 
of stable Foxp3 (+) Tregs that are primarily generated in the 
thymus (tTregs) (17). Therefore, FOXP3 and CD25 expression 
is reduced in Tregs from BLT-treated patients independently of 
Helios expression.
Interestingly, within the CD4+CD25hiCD127lo/− region, 
we found that only patients under CsA treatment showed a 
reduced percentage of FOXP3+ cells compared to controls 
(76.80 ± 2.83 versus 88.46 ± 1.20; p = 0.002); while the percent-
age of FOXP3+ cells within this region was not significantly 
altered in kidney transplant patients under BLT treatment 
compared to controls (83.29  ±  2.39 versus 88.46  ±  1.20; 
p  =  0.07). Furthermore, some CsA-treated patients (three 
out of seven) showed a proportion of FOXP3+ cells outside 
the characteristic CD4+CD25hiCD127lo/− region (Figure S1 in 
Supplementary Material).
Tregs from BlT-Treated Patients Display 
impaired suppressive Function
To determine whether the long-term immunosuppressive thera-
pies had any effect in Treg function, CD4+CD25hi T cells were 
purified from each group for in vitro suppression assays. As the 
percentage of CD25+FOXP3+ cells within the CD4+ subpopula-
tion was reduced in kidney transplant patients (Figure S2 in 
Supplementary Material), for the suppression assays a gate was 
set to sort Tregs containing >85% of CD4+CD25hiFOXP3+ T cells 
similar to the control group (CD4+CD25veryhi gate, Figure S3A 
in Supplementary Material). CD4+CD25hi T cells from controls 
were able to suppress proliferation of both autologous CD4+ and 
CD8+ T cells at all evaluated ratios. By contrast, CD4+CD25hi 
T cells isolated from CsA- and BLT-treated patients showed 
reduced suppression even at high ratios of Tregs to CD4+ T cells 
(BLT = 19.52 ± 5.16; CsA = 17.74 ± 6.81; control = 51.03 ± 5.52 
FigUre 2 | cD4+ T cells from BlT-treated patients show a diminished frequency of FOXP3+ subset with reduced levels of FOXP3 and cD25.  
(a) A reduced frequency of CD4+FOXP3+ T cells was found in patients under BLT (n = 21) and CsA (n = 10) treatment compared to controls (n = 9). Lefts panels 
show representative dot plots from patients and controls. (B) Levels of FOXP3 and CD25 expression within the CD4+ subpopulations, were calculated as mean 
fluorescence intensity (MFI), showing a significant reduction in BLT-treated patients compared to CsA and control group. Left panels show representative histograms 
from BLT (black solid line), CsA (gray solid line), and control (filled histogram) individual; dotted line denotes fluorescence minus one control. MFI values from each 
individual were calculated by subtracting the MFI values of the non-expressing subpopulation for each marker from the corresponding expressing subpopulation. 
Statistical analysis was performed using non-parametric Mann–Whitney test, two tailed. BLT, belatacept; CsA, Cyclosporine A. Control group was composed by 
healthy individuals.
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at 1:2 ratio; p <  0.01) and CD8+ T cells (BLT =  17.31 ±  4.83; 
CsA =  21.67 ±  3.20; control =  53.31 ±  5.66 at ratio 1:2 ratio; 
p < 0.01) (Figure 6), being associated with the reduced levels of 
FOXP3 and CD25 observed in the isolated CD4+CD25hi T cells 
of all kidney transplant patients (Figure S3B in Supplementary 
Material). The suppressive capacity of Tregs was not significantly 
different between BLT- and CsA-treated patients. Of note, in the 
absence of Tregs, T cells from patients were equally able to pro-
liferate after anti-TCR stimulation (Figure S4 in Supplementary 
Material).
FigUre 3 | Peripheral cD4+cD25hicD127lo/−FOXP3+ T cells [regulatory T cells (Tregs)] from kidney transplant patients showed a reduction in 
frequency and expression levels of FOXP3. (a) Reduced frequency of CD4+CD25hiCD127lo/− T cells in long-term kidney transplant patients (BLT = 12 and 
CsA = 7) versus controls (n = 9). Right panels show representative dot plots from patients and controls. (B) Reduction in the percentage of 
CD4+CD25+CD127lo/−FOXP3+ T cells in compared to controls. (c) Expression of markers characteristic of the Treg phenotype demonstrates a significant reduction 
of FOXP3 and CD25 in Tregs from BLT-treated patients. Left panels show representative histograms from BLT (black solid line), CsA (gray solid line), and control 
(filled histogram) individual; dotted line is a fluorescence minus one control. Mean fluorescence intensity (MFI) values from each individual were calculated by 
subtracting the MFI values of the non-expressing subpopulation for each marker from the corresponding expressing subpopulation. Statistical analysis was 
performed using non-parametric Mann–Whitney test, two tailed. BLT, belatacept; CsA, Cyclosporine A; control group was composed by healthy individuals.
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FigUre 4 | reduced FOXP3 expression on BlT regulatory T cells (Tregs) is not a consequence of the accumulation of Tregs with naïve phenotype. 
Patients under BLT treatment showed an increase frequency of naïve Tregs (a); however, a reduced expression of FOXP3 (B) was found in both naïve (CD45RA+) 
and activated (CD45RA−) Tregs from patients under BLT (n = 14) treatment compared to CsA (n = 4) and controls (n = 9). (c) CD25 expression was significantly 
reduced in activated but not naïve Tregs from BLT patients. Statistical analysis was performed using non-parametric Mann–Whitney test, two tailed. BLT, belatacept; 
CsA, Cyclosporine A. Control group was composed by healthy individuals.
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Tregs from BlT-Treated Patients slightly 
reduced iFn-γ by activated T cells
To investigate whether the impaired ability of Tregs from patients 
to inhibit T cell proliferation was accompanied by a reduced 
production of cytokines by responders T cells, we analyzed the 
cytokine secretion in the culture supernatants of the same sup-
pression assays. As shown in Figure 7A, we found a decrease in 
the production of IFN-γ in the cocultures compared to respond-
ers T cells alone when patient’s Tregs were used. This reduction 
was lower in BLT-treated patients to that observed in cultures 
of CsA and controls. Interestingly, although the production of 
IL-2 in responder T cells alone was similar between controls and 
BLT-treated patients, the levels of IL-2 were not significantly 
reduced in the cocultures from these patients compared to 
controls (Figure 7B). By contrast, a reduced production of IL-2 
was found in responders T cells alone and cocultures from CsA-
treated patients.
FOXP3 TsDr is Methylated in Tregs from 
BlT- and csa-Treated Patients
It has been previously reported that stable expression of FOXP3 
is important to maintain Treg function (18), therefore we next 
analyzed the methylation state of the FOXP3 TSDR from isolated 
CD4+CD25hi T cells of transplanted patients and controls, which 
were previously used for suppression assays (CD4+CD25veryhi 
gate, Figure S3A in Supplementary Material). As FOXP3 gene is 
located into X chromosome, we evaluated only male individuals 
and the results were reported as percentage of methylated CpG 
FigUre 5 | FOXP3 expression is reduced in regulatory T cells (Tregs) from BlT-treated patients independently of helios expression. (a) No differences 
in the frequency of Helios+ on Tregs population from the three evaluated groups. (B) Reduced expression of FOXP3 within Helios+ (left panel) or Helios− Tregs (right 
panel) of transplanted patients (BLT = 19 and CsA = 7) compared with control group (n = 9). (c) CD25 expression was significantly reduced in Helios− but not in 
Helios+ Tregs from BLT patients. Statistical analysis was performed using non-parametric Mann–Whitney test, two tailed. BLT, belatacept; CsA, Cyclosporine A. 
Control group was composed by healthy individuals.
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(of a total of 15) from five positive clones obtained from each 
individual. When we analyzed the percentage of methylation 
from all CpG sites sequenced, we observed a variability in kidney 
transplant patients, where some patients were almost all methyl-
ated (BLT2 and CsA2) and others showed a full demethylation 
(BLT3 and CsA1) independently of immunosuppressive treat-
ment, compared to controls where almost all clones sequenced 
were demethylated (Figure 8B). As a result, the complete analysis 
of all patients showed a significant increase in the percentage of 
methylation in the FOXP3 TSDR in Tregs from BLT- and CsA-
treated patients compared to controls (Figure 8C). This enhanced 
methylation could be associated with the reduced of suppression 
observed in Tregs from transplanted patients (Figure 6).
DiscUssiOn
Regulatory T cells have been implicated in tolerance induction 
to allogeneic organ transplantation (13). Thus, it is important to 
ensure that immunosuppressive drugs do not interfere in Treg 
development and/or function (19). Studies have reported that kid-
ney transplant patients under BLT treatment show a better renal 
function and less chronic nephropathy in comparison to those 
FigUre 6 | impaired suppressive function of regulatory T cells (Tregs) from kidney transplant patients. (a) Histograms show cells proliferation of carboxy 
fluorescein succinimidyl ester (CFSE)-labeled CD3+ T cells in the absence (responder T cells alone) or presence of Tregs (CD4+CD25veryhi gated) from kidney 
transplant patients (BLT and CsA) or healthy subjects (control), numbers indicate the percentage of dividing cells. One representative experiment is presented.  
(B) CD4+CD25hi T cells (Treg) isolated from BLT- (black bars, n = 9) or CsA- (gray bars, n = 4) treated patients showed impaired suppression of both autologous 
responder CD4+ and CD8+ T cell (Tresp) proliferation at all evaluated Tregs:Tresp ratios, compared to controls (white bars, n = 8). There were no significant 
differences between Tregs from BLT- and CsA-treated patients. Suppression was calculated as relative inhibition using the following formula: [(Tresp proliferation 
without Tregs − Tresp proliferation with Tregs)/Tresp proliferation without Tregs] × 100. Statistical analysis was performed using non-parametric Mann–Whitney test, 
two tailed. BLT, belatacept; CsA, Cyclosporine A.
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under CsA treatment (4, 6, 20). Some studies claim that Treg fre-
quency in peripheral blood and transplanted organs are increased 
in patients under BLT treatment (9, 21); however, other studies 
claim the opposite (12). Such differences may be caused by incon-
sistent parameters used for the characterization of the total Treg 
pool, different gating strategies and small numbers of participants 
in many studies. In the present study, we found no differences in 
the frequency of Treg (CD4+CD25hiCD127lo/−FOXP3+), between 
patients under BLT and CsA treatment, although they were lower 
than those found in healthy individuals. In this study, we used, 
besides the CD25+ and FOXP3+ markers, the low expression of 
CD127 to identify Tregs that were evaluated in 35 patients with a 
mean time of 7 years since transplantation. By contrast, analysis 
of Tregs in other studies was based on CD25 and FOXP3 expres-
sion (9), two markers that are transiently expressed in activated 
humans T cells (22), and other results were limited by the small 
numbers of patients included in the study (21).
Helios was initially reported as a marker of Treg generated 
in the thymus and was used to differentiate tTregs from those 
generated in the periphery (23). However, recent reports have 
shown that Helios can be expressed in peripherally induced 
Tregs and is associated with T cell activation and cell division 
FigUre 7 | iFn-γ and il-2 production in suppression cocultures from kidney transplant patients. Cytokines were measured in the supernatant cultures of 
suppression assays from kidney transplant patients (BLT = 3 and CsA = 4) and controls (n = 4), after a stimulus with beads CD3/CD28 (responder T cells alone) or 
cocultured with autologous regulatory T cells (Tregs) by 4 days. (a) Responder T cells alone from transplanted individuals produce IFN-γ after CD3/CD28 stimulus in 
the same way of controls, and this production is reduced in the presence of autologous Tregs. Tregs from BLT-treated patients slightly reduced IFN-γ production by 
activated T cells. (B) Alterations in IL-2 production were observed in transplanted individuals compared with controls. Responder T cells alone from BLT but not 
CsA-treated patients produce normal levels of IL-2. Statistical analysis was performed using non-parametric Mann–Whitney test, two tailed. BLT, belatacept; CsA, 
Cyclosporine A. Control group was composed by healthy individuals.
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(24). Interestingly, it was reported that FOXP3+Helios+ Tregs 
represent a much more stable population as they differ from 
FOXP3+Helios− Tregs in their epigenetic status of the FOXP3 
locus and their capacity to produce effector cytokines (25). Our 
results suggest that Helios expression is not responsible for the 
levels of FOXP3, as this marker was similarly downregulated in 
Helios+ and Helios− Tregs from kidney transplant patients, com-
pared to controls (Figure 5). Similarly, an accumulation of “naïve” 
Tregs cannot account for the reduced expression of FOXP3 on 
Tregs from BLT-treated patients, as it was affected in both “naïve” 
(CD45RA+) and “activated” (CD45RA−) Tregs (Figure 4).
It has been argued that the immunosuppressive drugs used 
to maintain graft acceptance in kidney transplant patients may 
be affecting both the development, homeostasis, and function of 
Tregs (26); BLT blocks T cell signaling by inhibiting the CD28 
costimulatory pathway while CsA inhibits the synthesis of NFAT-
dependent cytokines such as IL-2. Previous studies have shown 
that both CD28 and IL-2 pathways signaling are essential for 
sustained expression of FOXP3 in Treg cells and maintenance 
of a stable phenotype in the periphery (27, 28). In this study, 
transplanted patients showed a lower MFI of FOXP3, which is 
associated with lower suppressor function in vitro (Figure 6).
Besides of blocking proliferation, Tregs are able to inhibit the 
production of cytokines and prevent the differentiation of immune 
cells. We observed that Tregs from BLT-treated patients slightly 
reduced IFN-γ production despite their impaired suppressive 
function on T cell proliferation (Figure 7A). In this context, it has 
been reported that Tregs can inhibit IFN-γ production without 
blocking the proliferation of CD4+ T cells (29). Moreover, their 
suppressor effects on TCR signaling, IL-2/IFN-γ transcription 
as well as IFN-γ production were retained in conventional T 
cells after the removal of Tregs (30). So, it is probable that Tregs 
require a more prolonged cellular contact to be able in suppress 
the proliferation of immune cells (31). A reduction or alteration 
of membrane markers as CTLA-4 or defects in expression of 
receptors to IL-2 (CD25) could explain the lack of suppression of 
proliferation observed in our transplanted patients. In this con-
text, Tregs from BLT-treated patients showed diminished CD25 
FigUre 8 | altered methylation in the regulatory T cell (Treg) FOXP3 TsDr from kidney transplant patients. Sequence analysis of the TSDR region of the 
FOXP3 gene from BLT, CsA, or controls (three male individuals per group, five clones per individual). (a) After bisulfite treatment, all demethylated CpG cytosines 
(blue) convert to thymines (red), as seen with CD4+CD25hi Tregs from the control (CD4+CD25veryhi gated). By contrast, naïve T cells display a completely methylated 
TSDR and were used as negative control. Data from representative individuals from each group are shown. (B) The panel shows the methylation status of the TSDR 
FOXP3 in the indicated T cells from the three evaluated groups (three individuals per group). Each square represents one CpG analyzed, data are presented as 
mean percentage methylation of five clones per individual. Methylation color code ranges from yellow (0% methylation) to blue (100% methylation) according to the 
color scale (upper right). (c) Percentage of demethylation from each evaluated group, represented as the ratio between the numbers of demethylated cytosines and 
the total number of sequenced CpG sites within the TSDR region.
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expression (Figure 3C) which could affect the “consumption” of 
IL-2 by Tregs, explaining the lack of IL-2 depletion observed in 
the cocultures with Tregs from these patients (Figure 7B).
Many reports have claimed the “division of labour” between 
distinct Treg subpopulations in the maintenance of tolerance 
(32). In the context of allospecific tolerance, it has been claimed 
that tTregs may participate in the inhibition of T-effector cell traf-
ficking to the target organ while antigen-specific iTregs primarily 
prevent T-cell priming by acting on antigen-presenting dendritic 
cells (33). Therefore, it would be relevant to analyze the impact 
13
Alvarez Salazar et al. Altered Tregs in Belatacept-Treated Patients
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 219
of inmunosuppressors in the percentage and/or function of both 
subpopulations. Our data showed a decrease in percentage and 
suppressor function of circulating Tregs; however, no specific 
markers are currently available to reliably distinguish thymic 
versus peripherally induced Treg populations (24).
Although there is a previous study claiming that neither 
BLT nor CsA affect the normal function of Treg cells (11), the 
current study analyzed the patient’s Treg suppressor capacity 
on responder T cells from the same kidney transplant patients, 
while the former one used responder T cells from their respective 
donors. Interestingly, we were unable to detect strong direct allo-
reactive responses from our transplanted patients toward their 
donors APCs, even in the presence of exogenous IL-2 (data not 
shown), which suggests a possible deletion of direct allospecific T 
cells. In addition, in long-term kidney transplant patients as those 
included in this study, alloreactive T cells may likely recognize 
alloantigens by an indirect pathway (34), and thus suppression 
function of Tregs on alloreactive T cells activated by this pathway 
should be pursued. Therefore, we cannot exclude the possibility 
that Tregs cells with an indirect pathway of allospecificity may 
have a normal suppressor function. It is not clear whether the 
relevant allospecific Treg subpopulation of long-term kidney 
transplant patients can be found in peripheral blood or rather 
it has migrated to the transplanted organ to accomplish its func-
tion, as has been suggested (8).
Our study showed that some transplanted patients display 
a low frequency and decreased expression of FOXP3 within 
CD4+CD25hiCD127lo/− region (Figure  3), which was previ-
ously reported for CsA-treated patients (35). In addition to 
affecting the generation or homeostasis of the Treg pool, this 
reduction may be caused by the fact that some Tregs might 
lose its FOXP3 expression due to the action of the immuno-
supressors on FOXP3 stability, that is controlled by epigenetic 
and post-translational modifications (36, 37). In this context, 
demethylated TSDR (Treg-specific demethylation region) of 
the FOXP3 gene is indicative of stable FOXP3 expression and 
Treg lineage commitment (36). Unlike other studies which 
analyzed the methylation state of total PBMC by real time PCR 
(38), here we decided to sequence the whole TSDR region of 
sorted Tregs to obtain a more complete information about the 
epigenetic status of the FOXP3 TSDR in this subpopulation. 
Interestingly, our data showed that transplanted patients under 
BLT or CsA treatment presented partial methylation of the 
CpG islands present in the TSDR (Figure 8), which is associ-
ated with the impaired suppressor function from Tregs of these 
patients. Thus, the loss of demethylation in TSDR region might 
be responsible for the reduced FOXP3 expression observed in 
these patients, and lower levels of FOXP3-dependent markers 
such as CD25 and CTLA-4 (39, 40), where its upregulation is 
associated with enhanced Treg activity (28, 41). It has been 
reported that ten–eleven translocation (TET) enzymes might 
participate in the demethylation of FOXP3 (42). TET enzymes 
catalyzes the conversion of 5-methylcytosine (5mC) to 
5-hydroxymethylcytosine that are intermediates in the process 
of DNA demethylation. High expression of these enzymes was 
observed in thymic FOXP3+ Treg subsets and a deletion of TET 
enzymes led to FOXP3 hypermethylation (43). In addition, 
high expression of TET enzymes have been observed after TCR 
signaling and IL-2 was necessary to maintain their expression 
(44) and, it was shown that (IL-2)-activated Stat5 facilitated Tet1 
and Tet2 binding to FOXP3. On other hand, CD28 signaling in 
Tregs is required for stabilization of FOXP3 mRNA in thymic 
Treg precursors (45). Therefore, the block of these pathways by 
immunosuppressive drugs could explain the methylation in the 
FOXP3 TSDR observed in transplanted patients under BLT and 
CsA treatment.
The variability found in the percentages of GpG island 
demethylation from the TSDR region of patients under 
immunosuppressive treatment suggests that the impaired 
suppressor function of Tregs from transplanted patients may 
also be caused by FOXP3-independent factors, such as IL-10, 
TGFβ, granzyme B, and galectin-1 (46). Therefore, although 
our results are suggestive of the impact of BLT and CsA on 
TSDR methylation, it is necessary to include other pheno-
typic and functional analysis to determine the mechanism 
underlying the alterations of Tregs in long-term transplanted 
patients.
Our findings suggest that circulating Tregs are no solely 
responsible for the quiescence immune state achieved in stable 
long-term patients. In this context, a recent study showed 
BLT-treated patients have increased cellular populations with 
regulatory function such that IL-10+ B cells and IDO+ cells (9, 
47), which could promote tolerance during transplantation and 
facilitate the long-term survival and function of allografts.
In summary, this study has shown that even in patients 
with stable graft function, treatment with BLT can have an 
advertent effect on Treg, suggesting that the beneficial effects 
reported by BLT cannot be only explained by circulating Tregs. 
However, we cannot exclude the immunomodulatory role 
of Tregs, as allospecific Treg function has not directly been 
evaluated. Interestingly, a report showed that combination of 
T cell depletion, BLT, and Sirolimus favored Treg expansion 
and abrogation of T-cell alloreactive anti-donor responses 
in vitro, although the study was performed only at 12 months 
of transplantation (48). Whether the drug effects on Tregs have 
an impact on the ultimate outcome of renal allografts remains 
unclear. Therefore, the effects of long-term immunosuppres-
sion on Tregs should be taken into account in the design of new 
Treg-based therapy.
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